Salma Pothiawala, Mei-Yu Hsu, Clarissa Yang, Santosh Kesari, Omar A Ibrahimi
Index: Journal. of. Drugs in. Dermatology. 9(9) , 1142-4, (2010)
Full Text: HTML
Temozolomide is an oral alkylating agent approved for the treatment of glioblastoma and anaplastic astrocytoma, and is currently under clinical investigation for the treatment of brain metastases from a variety of cancers. Temozolomide is well tolerated, and the reported dermatologic side effects of this medication are limited. Here, the authors report the first case of an urticarial hypersensitivity reaction induced by temozolomide. As this drug will likely be increasingly utilized in the near future, it is important to be aware of its potential to cause adverse cutaneous manifestations.
| Structure | Name/CAS No. | Molecular Formula | Articles |
|---|---|---|---|
![]() |
FLUOCINONIDE
CAS:356-12-7 |
C26H32F2O7 |
|
Effects of a novel formulation of fluocinonide 0.1% cream on...
2011-02-01 [Journal. of. Drugs in. Dermatology. 10(2) , 171-6, (2011)] |
|
In vivo determination of the skin atrophy potential of the s...
2008-01-01 [Journal. of. Drugs in. Dermatology. 7(1) , 28-32, (2008)] |
|
The efficacy of three class I topical synthetic corticostero...
2009-08-01 [Journal. of. Drugs in. Dermatology. 8(8) , 751-5, (2009)] |
|
Reticulated phototoxic eruption in a patient on long-term di...
2008-08-01 [Journal. of. Drugs in. Dermatology. 7(8) , 792-3, (2008)] |
|
Improvement in treatment adherence with a 3-day course of fl...
2010-10-01 [Cutis. 86(4) , 208-13, (2010)] |
Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer
Copyright © 2024 ChemSrc All Rights Reserved
